Tesamorelin – 20 mg

Tesamorelin is a synthetic analogue of human growth hormone-releasing factor (GHRF), consisting of the 44-amino-acid sequence of human GHRF with a modified N-terminal structure. In laboratory studies, tesamorelin binds to and stimulates human GHRF receptors, making it a useful research compound for investigating growth hormone-axis signaling. The 20 mg presentation is intended for qualified research environments conducting controlled investigations into GHRF receptor activity, growth hormone signaling, peptide pharmacology, endocrine pathways, and related cellular mechanisms.

Key Features

20 mg research-grade tesamorelin Synthetic GHRF / GHRH analogue 44-amino-acid peptide sequence derived from human GHRF Relevant to growth hormone receptor-axis research Suitable for peptide pharmacology and signaling studies Intended for controlled in-vitro and preclinical research Appropriate for peptide characterization and analytical workflows Batch-level analytical documentation may be provided for applicable lots Research Focus Tesamorelin is studied for its interaction with the human GHRF receptor and its relationship to growth hormone signaling. Research applications may include investigations of receptor pharmacology, GH-axis biology, peptide structure, and downstream signaling pathways. Tesamorelin has also been clinically characterized as a GHRF analogue that stimulates endogenous growth hormone secretion and can increase IGF-1 levels.

Important Notice

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, or prevention of disease. This research material should be handled only by appropriately qualified personnel in accordance with applicable laboratory protocols and regulations.